Basecamp Research has secured $140 million in funding from Nvidia and Anthropic's Anthology Fund to train AI models on genetic sequences. The London startup uses biological data from extreme environments to design antibiotics and cell therapy tools.
Basecamp Research mines genetic material from rainforests, oceans, and hot springs to train machine learning models for drug discovery. The approach treats evolution as training data, leveraging billions of years of biological experimentation.
CTO Phil Lorenz argues biology presents a fundamentally different problem for AI than language processing. Unlike text-based models, biological AI must bridge the gap between in-silico predictions and real-world molecular performance.
The startup focuses on two applications: designing novel antibiotics to combat resistant infections, and developing tools for cell therapies. Basecamp's funding round demonstrates investor confidence in computational biology as a path to accelerated drug development.
The company's thesis rests on a critical insight: high benchmark scores don't guarantee functional molecules. Successful AI in this space requires models that produce compounds with practical efficacy, not just theoretical promise.
The market for open-source AI models is consolidating around a handful of dominant players, with Meta's Llama, Mistral, and other frameworks competing for developer mindshare and enterprise adoption.
Alibaba's Qwen team released Qwen-Audio-3.1, a suite of five models for speech and audio processing, while cutting prices up to 95 percent across its AI audio services.
China has surpassed the United States as the leading destination for elite AI talent, capturing 40.6% of top researchers by 2025, up from 27.1% in 2022. The US share declined to 34.2% from 46.4% over the same period.
President Trump is set to meet China's Xi Jinping while Congress considers legislation to restrict artificial superintelligence development, despite minimal regulatory progress to date.